Thrombolysis in Myocardial Ischemia Trial (TIMI III)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The Thrombolysis in Myocardial Ischemia Trial (TIMI III) focused on unstable angina and non-Q-wave myocardial infarction. The trial was designed to determine by coronary arteriography the incidence of coronary thrombi in these conditions and the response of these thrombi to tissue-type plasminogen activator (t-PA) in TIMI IIIA and the effects of thrombolytic therapy and of an early invasive strategy on clinical outcome in TIMI IIIB. There was also a registry with two components. A roster enumerated all patients with unstable angina or non-Q-wave myocardial infarction enrolled at cooperating hospitals. From the roster, a study population of 1,893 subjects was selected and followed prospectively for the year to determine incidence of death or myocardial infarction.
Condition | Intervention | Phase |
---|---|---|
Angina Pectoris Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Infarction Myocardial Ischemia |
Drug: tissue plasminogen activator Drug: heparin |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Masking: Double-Blind Primary Purpose: Treatment |
Ages Eligible for Study: | 21 Years to 76 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Men and women, ages 21 to 76, with unstable angina or non-Q-wave myocardial infarction.
Publications:
ClinicalTrials.gov Identifier: | NCT00000472 History of Changes |
Other Study ID Numbers: | 61 |
Study First Received: | October 27, 1999 |
Last Updated: | June 23, 2005 |
Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
Angina Pectoris Cardiovascular Diseases Myocardial Ischemia Coronary Artery Disease Coronary Disease Heart Diseases Infarction Ischemia Myocardial Infarction Vascular Diseases Chest Pain Pain Signs and Symptoms Arteriosclerosis |
Arterial Occlusive Diseases Pathologic Processes Necrosis Heparin Plasminogen Tissue Plasminogen Activator Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents |
ClinicalTrials.gov processed this record on February 24, 2013